Source: International Congress 2015 – Asthma and lung immunology
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Christian Domingo Ribas (Sabadell (Barcelona), Spain), Christian Domingo, Xavier Pomares, Albert Navarro, Carles Grimau, Ana Sogo, Rosa Mirapeix. Omalizumab is equally effective in persistent allergic oral corticosteroid-dependent asthma whether due to seasonal allergens or to perennial allergens. Eur Respir J 2015; 46: Suppl. 59, 1097

Member's Comments

No comment yet.

Related content which might interest you: Subcutaneous allergen specific immunotherapy and immunological response in patients with bronchial asthma and allergic rhinitis in India Source: International Congress 2014 – Intervening in allergic asthma Year: 2014 Omalizumab in the treatment of perennial allergic rhinitis Source: Eur Respir J 2001; 18: Suppl. 33, 37s Year: 2001 Combined therapy of asthma and allergic rhinitis Source: Annual Congress 2013 –Treatment of asthma Year: 2013 Asthma control with omalizumab treatment in severe allergic asthma and severe non-allergic asthma patients Source: International Congress 2015 – Asthma and lung immunology Year: 2015 HDM sublingual AIT tablet is well-tolerated and effective in partly and uncontrolled allergic asthma Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014 The ’real-life’ long-term efficacy of omalizumab in severe persistent IgE-mediated allergic asthma in Malta Source: International Congress 2016 – Asthma management Year: 2016 Treatment of co-morbid allergic asthma and perennial allergic rhinitis with the anti-IgE agent omalizumab Source: Eur Respir J 2003; 22: Suppl. 45, 203s Year: 2003 QAV680, cetirizine and their combination reduce nasal symptoms in patients with intermittent allergic rhinitis in an environmental exposure chamber Source: International Congress 2014 – Allergy and asthma: novel findings based on human cell biology Year: 2014 Sputum eosinophilia in severe allergic asthma is not a reliable marker of omalizumab treatment Source: International Congress 2015 – Immune mechanisms in the human lung Year: 2015 Efficacy of omalizumab in allergic asthma by asthma severity and eosinophilic status Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis Year: 2015 Safety of 5-grass pollen extract sublingual tablet in patients with grass pollen-induced allergic rhinoconjunctivitis and concomitant intermittent asthma: A pooled analysis Source: Annual Congress 2013 –Treatment of asthma Year: 2013 Comparative efficacy of different groups of drugs for the treatment of bronchial asthma in combination with allergic rhinitis Source: International Congress 2014 – Intervening in allergic asthma Year: 2014 Efficacy of ruzam in the treatment of patients with perennial allergic rhinitis Source: Eur Respir J 2004; 24: Suppl. 48, 131s Year: 2004 Asthma among birch-pollen allergic patients Source: Eur Respir J 2005; 26: Suppl. 49, 132s Year: 2005 Asthma among allergic rhinitis patients Source: Eur Respir J 2003; 22: Suppl. 45, 108s Year: 2003 Sublingual immunotherapy is an established therapy for house dust mite sensitive allergic rhinitis and/or asthma Source: Annual Congress 2007 - Improving asthma therapy - new findings in established and experimental treatment modalities Year: 2007 Should patients with mild asthma be excluded from allergic rhinitis drug trials? Source: International Congress 2015 – Immune mechanisms in the human lung Year: 2015 Specific allergen immunotherapy of asthma combined with allergic rhinitis Source: Eur Respir J 2006; 28: Suppl. 50, 441s Year: 2006 Evaluation of six-year allergen immunotherapy in allergic rhinitis and allergic asthma Source: Eur Respir J 2006; 28: Suppl. 50, 439s Year: 2006 Comorbidity of allergic rhinitis and asthma to birch allergen in an environmental exposure chamber Source: International Congress 2015 – Immune aspects of asthma and other airway diseases Year: 2015